# Anne Horgan

> Anne Horgan is a Series A investor at Cambridge Innovation Capital backing Medical. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Cambridge Innovation Capital](https://shizune.co/investors/profile/cambridge-innovation-capital)
- Location: Paris, France
- Total investments: 3
- Last investment: Apr 2023
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/anne-horgan-nee-nguyen/5/361/a54

Anne Horgan is a Partner at Cambridge Innovation Capital.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 67% |
| Biotechnology | 2 | 67% |
| Banking | 1 | 33% |
| Aerospace | 1 | 33% |
| GreenTech | 1 | 33% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 67% |
| Private Equity | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Complement Therapeutics | Complement Therapeutics operates as a preclinical stage company. Complement Therapeutics develops a precision medicine diagnostic platform allowing it to stratify patients based on their complement-activation profile with the potential to enable both patient selection and serving as an efficacy biomarker in future clinical studies. | $78.7M | Series A | Apr 17, 2023 |  |
| Mosaic Therapeutics | Mosaic Therapeutics is an oncology therapeutics company that develops targeted combination therapies for cancer patients. The company utilizes a proprietary platform to identify synergistic drug combinations based on biomarker-defined patient populations, aiming to improve the efficacy and durability of responses. Mosaic Therapeutics' researchfocuses on identifying specific biomarkers that can be targeted with tailored drug combinations, enhancing the effectiveness of treatments for individual patients. | $28M | Series A | Apr 04, 2023 |  |
| Botanical Ventures Limited | Botanical Ventures Limited is a privately held company based in London, United Kingdom, and has been incorporated since 2017. The company brings together a diverse range of industries — including financial services, asset tokenization, mining operations, real estate, biotechnology, and botanical ventures — with a focus on building real-world valuethrough innovation and cross-sector expertise.Co-founded by Alexander Thomas Dover and Nicolas-André Borel, Botanical Ventures Limited operates with a vision to connect traditional industries with emerging technologies. While Alexander leads the company’s strategic direction, Nicolas-André serves as Chief Operating Officer, playing a key role in driving operational growth and cross-border initiatives.Registered under UK company law, Botanical Ventures is committed to long-term, sustainable development and creating new opportunities across both established and frontier markets. | $5.5M | Private Equity | Feb 10, 2022 |  |

3 of 3 investments shown.

## Co-investors
- [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 2 deals together
- [Syncona Partners LLP](https://shizune.co/investors/profile/syncona-partners-llp) — VC Fund, 2 deals together
- [BioGeneration Ventures](https://shizune.co/investors/profile/biogeneration-ventures) — VC Fund, 1 deal together
- [British Patient Capital](https://shizune.co/investors/profile/british-patient-capital) — VC Fund, 1 deal together
- [Gimv](https://shizune.co/investors/profile/gimv) — VC Fund, 1 deal together
- [Hadean Ventures](https://shizune.co/investors/profile/hadean-ventures) — VC Fund, 1 deal together

## About Cambridge Innovation Capital

VC Fund · Cambridge, United Kingdom

Cambridge Innovation Capital backs life sciences and technology companies with an affiliation to Cambridge, Europe’s capital for innovation. As a preferred investor for the University of Cambridge, they have unparalleled access to investment opportunities in the ecosystem.Since our inception in 2013, they have raised £275 million to invest indisruptive, deep-tech businesses in sectors including, but not limited to, artificial intelligence, the internet of things, quantum technologies, autonomous systems, therapeutics, medtech/diagnostics, digital health, and genomics/proteomics.

5 contacts available at Cambridge Innovation Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Anne Horgan | Partner | https://shizune.co/investors/profile/anne-horgan |
| Damian Crowther | Entrepreneur In Residence | https://shizune.co/investors/profile/damian-crowther |
| Edward Benthall | Chairman | https://shizune.co/investors/profile/edward-benthall |
| Humphrey Battcock | Independent Non-executive Director | https://shizune.co/investors/profile/humphrey-battcock |
| Ian Jauncey | Operating Partner | https://shizune.co/investors/profile/ian-jauncey |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Anne Horgan invest in?

Anne Horgan invests primarily in Medical, Biotechnology and Banking startups, most often at Series A and Private Equity stage. Most of the 3 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Anne Horgan last invest?

The most recent investment recorded for Anne Horgan closed in Apr 2023. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co